close_game
close_game

Anti-obesity class of drugs linked to fewer post-surgery complications: Study

PTI | | Posted by Tapatrisha Das, New Delhi
Jan 07, 2025 01:30 PM IST

GLP-1 RA drugs help treat diabetes by weight loss, improving blood glucose levels and increasing insulin sensitivity, low levels of which can lead to diabetes.

Taking the 'GLP-1 receptor agonist' class of anti-obesity drugs is related with lower rates of post-surgery complications in people with diabetes, according to a study.

Patients taking the anti-obesity drugs had about 12 per cent lower risk of hospital re-admission within a month of surgery.(Unsplash)
Patients taking the anti-obesity drugs had about 12 per cent lower risk of hospital re-admission within a month of surgery.(Unsplash)

GLP-1 receptor agonist, or GLP-1 RA, drugs help treat diabetes by weight loss, improving blood glucose levels and increasing insulin sensitivity, low levels of which are a risk factor for diabetes.

Researchers, led by those at Weill Cornell Medicine, the US, analysed hospital records of over 74,400 surgical procedures performed from February 2020 to July 2023 on nearly 22,000 patients with diabetes. Also read | Controversial weight loss drug linked to Karan Johar: Is Ozempic safe or a health risk?

Anti-obesity drugs and post-surgery complications: What's the link?

Patients taking the anti-obesity drugs had about 12 per cent lower risk of hospital re-admission within a month of surgery, compared to those not taking these medications, according to the findings published in the journal 'Annals of Surgery'.

The team also found 29 per cent lower risk of wound re-opening within six months of surgery, and about 56 per cent lower risk of haematoma -- when blood collects in a tissue due to an injury at the surgery site -- in this group of patients.

"These findings from such a large number of patients and procedures suggest that taking these drugs shouldn't worsen overall post-surgical complications, and may even reduce the likelihood of some of them," senior author Dr Jason Spector, chief of the division of plastic and reconstructive surgery and a professor of surgery at Weill Cornell Medicine, said. Also read | Powerful new obesity drug poised to upend weight loss care

For the analysis, the researchers recorded the rates of 30-day hospital re-admissions and post-surgical adverse events during the follow-up period of at least six months. The rates were compared among patients with and without active GLP-1 RA drug prescriptions.

The results showed that the patients who were prescribed GLP-1 RA drugs were modestly less likely to require hospital re-admission within 30 days of surgery, implying fewer overall complications.

"An active perioperative GLP-1 RA prescription in patients with diabetes was associated with significant reductions in risk-adjusted readmission, wound dehiscence (re-opening), and haematoma, and no difference in infection and bleeding rates," the authors wrote. Also read | Is your weight loss drug leading to muscle and bone loss? Study reveals shocking details

Disclaimer: This article is for informational purposes only and not a substitute for professional medical advice. Always seek the advice of your doctor with any questions about a medical condition.

rec-icon Recommended Topics
Catch every big hit, every wicket with Crick-it, a one stop destination for Live Scores, Match Stats, Quizzes, Polls & much more. Explore now!.

Catch your daily dose of Fashion, Taylor Swift, Health, Festivals, Travel, Relationship, Recipe and all the other Latest Lifestyle News on Hindustan Times Website and APPs.
See More
Catch every big hit, every wicket with Crick-it, a one stop destination for Live Scores, Match Stats, Quizzes, Polls & much more. Explore now!.

Catch your daily dose of Fashion, Taylor Swift, Health, Festivals, Travel, Relationship, Recipe and all the other Latest Lifestyle News on Hindustan Times Website and APPs.
SHARE THIS ARTICLE ON
SHARE
Story Saved
Live Score
Saved Articles
Following
My Reads
Sign out
New Delhi 0C
Wednesday, February 19, 2025
Start 14 Days Free Trial Subscribe Now
Follow Us On